Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.
CureVac B.V. (CVAC) is a clinical-stage biopharmaceutical leader pioneering mRNA technology for vaccines and cancer therapies. This page provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and scientific advancements.
Access verified press releases, earnings reports, and partnership announcements in one centralized location. Track progress across CureVac's clinical pipeline, including prophylactic vaccines, oncology treatments, and molecular therapies leveraging their proprietary mRNA platform.
Key updates cover:
• Clinical trial results
• Strategic collaborations with global partners
• Regulatory filings and manufacturing developments
• Financial performance and corporate communications
Bookmark this page for direct access to CureVac's official announcements, ensuring you stay informed about innovations in mRNA-based medicine and their market implications.
CureVac has announced its upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston from November 8-10, 2024. The company will showcase extended preliminary immunogenicity results from their Phase 1 CVGBM cancer vaccine study in glioblastoma patients.
Building on previous results presented at ESMO Congress, the study demonstrated that CVGBM monotherapy successfully induced cancer antigen-specific T-cell responses in 77% of evaluable patients, with 84% being de novo responses. Three poster presentations are scheduled, covering topics including preliminary immunogenicity results from the CVGBM trial, mRNA vaccination's enhancement of TCRtg T cell therapy efficacy, and T cell receptor identification for TP53 frameshift.
CureVac N.V. (Nasdaq: CVAC) presented promising Phase 1 data for its CVGBM cancer vaccine in glioblastoma patients at the ESMO 2024 Congress. Key findings include:
- 77% of evaluable patients showed cancer antigen-specific T-cell responses after CVGBM monotherapy
- 84% of immune responses were de novo
- 69% of responding patients showed CD8+ responses, 31% had CD4+ responses, and 23% had both
- CVGBM was well-tolerated up to 100 μg with no dose-limiting toxicities
- Most common adverse events were mild to moderate and resolved within 1-2 days
The 100 μg dose was selected for the ongoing dose expansion phase. These results suggest potential for CVGBM in cancer immunotherapy across various tumor types.
CureVac N.V. (Nasdaq: CVAC) announced that its partner GSK reported positive Phase 2 data from their seasonal influenza mRNA vaccine program. The vaccine candidate, based on CureVac's second-generation mRNA backbone, demonstrated positive immune responses against influenza A and B strains compared to current standards, meeting all predefined success criteria in both older and younger adult groups. The data suggests an acceptable safety and reactogenicity profile.
GSK confirmed that the data supports advancing the program to Phase 3, which would trigger a significant milestone payment for CureVac. This development follows the July 2024 agreement where GSK assumed full control of the influenza vaccine program. The Phase 2 study involved 500 participants across two age groups, testing different dose levels against licensed comparator vaccines.
CureVac N.V. (Nasdaq:CVAC) announced the presentation of first clinical data from its Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma at the ESMO Congress 2024. The study evaluates the safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-promoter unmethylated glioblastoma or astrocytoma. Key points:
- Oral presentation on September 13 will cover Part A results, including safety, tolerability, and initial immunogenicity data for dose levels of 12-100 μg
- Treatment-emergent adverse events were mostly Grade 1-2 with no dose-limiting toxicities
- CVGBM features a single unmodified mRNA encoding eight epitopes from tumor-associated antigens
- Part B enrollment began earlier this year, expected to include up to 20 additional patients at the recommended 100 μg dose
CureVac N.V. (Nasdaq:CVAC) announced financial results for Q2 and H1 2024, highlighting key developments:
- New licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront
- Strategic workforce reduction of ~30% by end of 2024
- Initiated Phase 1 study Part B in glioblastoma with CVGBM
- Cash position of €202.5 million as of June 30, 2024 (excluding €400 million GSK payment)
- Reaffirmed cash runway into 2028
Financial highlights for H1 2024:
- Revenues: €26.8 million (82% increase YoY)
- Operating loss: €146.9 million
- Pre-tax loss: €141.1 million
The company is focusing on high-value opportunities in oncology and infectious diseases while streamlining operations.
CureVac N.V. (Nasdaq: CVAC) has advanced its cancer vaccine candidate CVGBM to Part B of a Phase 1 study for patients with resected glioblastoma. The first patient has been administered in this dose-confirmation phase, which is expected to include up to 20 patients. Part B aims to generate extended data on safety, tolerability, and immunogenicity of CVGBM.
CVGBM is CureVac's first investigational cancer vaccine based on its second-generation mRNA backbone. It encodes a single fusion protein with eight epitopes showing immunogenicity in glioblastoma. The study's Part A, involving 16 patients and testing doses from 12 to 100 μg, has been completed with no dose-limiting toxicities reported. A 100 μg dose was recommended for Part B.
Initial data from Part A will be presented at the ESMO Congress on September 13, 2024.
CureVac N.V. (Nasdaq: CVAC) has appointed Dr. Mehdi Shahidi, a clinical oncologist and drug development expert, as an independent director to its Supervisory Board. Dr. Shahidi replaces Ralf Clemens, who served from March 2016 through September 2023. The appointment is effective at the CureVac SE level from September 2024, with consideration for CureVac N.V. at the next Annual General Meeting in June 2025.
Dr. Shahidi brings extensive experience in executive leadership and drug development, particularly in clinical oncology. He is currently the CEO of Petalion Therapeutics and a Venture Partner at Medicxi. His previous role as Senior Vice President, Global Head of Medicine and Chief Medical Officer at Boehringer Ingelheim International saw him oversee five drug approvals and advance over 30 candidates into clinical trials.
CureVac has announced updates on its ongoing patent litigation against Pfizer/BioNTech across the U.S., UK, and Germany. A U.S. trial date has been set for March 3, 2025, following a settlement with Acuitas Therapeutics that led to the withdrawal of three disputed patents. In Europe, the European Patent Office will decide on the validity of EP 3 708 668 B1 on March 25, 2025. German litigation sees a hearing scheduled in Düsseldorf on September 10, 2024. Meanwhile, a UK trial began on July 10, 2024, with a judgement expected later this year. These litigations involve patents related to split poly-A tail technology and COVID-19 vaccine design.
Agomab Therapeutics NV has appointed Pierre Kemula as its new Chief Financial Officer, effective November 1, 2024. Mr. Kemula joins from CureVac N.V. (Nasdaq: CVAC), where he led significant financial achievements, including a successful Nasdaq listing and raising over $1.6 billion in equity. He will replace Tolga Hassan, who recently departed to explore new opportunities. During the transition, Paul van der Horst has been serving as interim CFO. Agomab CEO Tim Knotnerus expressed confidence in Kemula’s expertise to drive the company’s growth. Kemula brings over 15 years of experience in biotech financial leadership, with previous roles at Pixium Vision, Ipsen, and major consulting firms.
CureVac has announced a strategic restructuring to focus on high-value mRNA pipeline opportunities, particularly in oncology and other critical diseases. This includes a 30% workforce reduction to create a leaner organization, emphasizing research and development. The company aims to deliver two clinical candidates by the end of 2025 and initiate two new Phase 1 studies by the end of 2026. A recent licensing agreement with GSK, worth up to €1.45 billion plus royalties, will extend CureVac's cash runway into 2028. Operational expenses are expected to decrease by over 30% from 2025, with one-time restructuring charges of approximately €15 million anticipated in Q4 2024.
